Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP4 | P15090 | 7/20 | 0.51 |
| ▸ | FABP3 | P05413 | 4/20 | 0.51 |
| ▸ | FABP5 | Q01469 | 2/20 | 0.51 |
| ▸ | CHEK1 | O14757 | 10/20 | 0.49 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.45 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.45 |
| ▸ | CDK2 | P24941 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | CLK1 | P49759 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3828856 | 0.92 | FABP4 (0.56) | FABP4FABP3FABP5CHEK1PLA2G10 | |
| SCHEMBL3825249 | 0.88 | PLA2G10 (0.43) | FABP4FABP3FABP5CHEK1PLA2G10 | |
| SCHEMBL4481685 | 0.86 | NPC1 (0.55) | FABP4FABP3FABP5CHEK1KDM4E | |
| SCHEMBL13675570 | 0.83 | FABP4 (0.47) | FABP4FABP3FABP5CHEK1PLA2G10 | |
| SCHEMBL13674672 | 0.80 | PLA2G10 (0.48) | FABP4FABP3FABP5CHEK1PLA2G10 | |
| SCHEMBL976455 | 0.71 | CDC7 (0.57) | CHEK1PLA2G10CCNE1CDK2KDM4E | |
| SCHEMBL1328083 | 0.70 | PLA2G10 (0.60) | CHEK1PLA2G10KDM4EALDH1A1NPC1 | |
| SCHEMBL29273322 | 0.70 | SMN1; SMN2 (0.47) | KDM4EALDH1A1NPC1RAB9A | |
| SCHEMBL1830741 | 0.70 | CHEK1 (0.69) | FABP4FABP3FABP5CHEK1PLA2G10 | |
| SCHEMBL29273332 | 0.69 | SMN1; SMN2 (0.48) | KDM4EALDH1A1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090270456-A1 | Novel chemical compounds | HASEGAWA MASAICHI | 2009-10-29 | — | — | US | claimed |
| US-20090270456-A1 | Novel chemical compounds | HASEGAWA MASAICHI | 2009-10-29 | — | — | US | disclosed |
| US-20090270456-A1 | Novel chemical compounds | HASEGAWA MASAICHI | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270456-A1 | Novel chemical compounds | HIPK3, HIPK2, HIPK1 | FABP4 3496/4885FABP3 796/4885FABP5 3065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.